Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
2.
Transfus Med Hemother ; 48(2): 132-133, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1314189
4.
Int J Infect Dis ; 102: 244-246, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-1059790

ABSTRACT

COVID-19 convalescent plasma (CCP) is widely used as a treatment. While safety data are enough, high-level evidences of efficacy are still missing. We summarize here the results from randomized controlled trials (RCT) published to date and analyze their flaws and biases. We then provide suggestions for next round of CCP RCTs, discussing specification of CCP, therapeutic dose, timing, control arm, disease stage, and outcome measures.


Subject(s)
COVID-19/therapy , Randomized Controlled Trials as Topic , SARS-CoV-2 , Humans , Immunization, Passive , Outcome Assessment, Health Care , COVID-19 Serotherapy
SELECTION OF CITATIONS
SEARCH DETAIL